[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-001", "question": "A 48-year-old woman with a history of systemic lupus erythematosus (SLE) on hydroxychloroquine and low-dose prednisone presents with 3 weeks of progressive dyspnea on exertion and dry cough. High-resolution CT shows diffuse ground-glass opacities with superimposed fine reticulation and subpleural sparing. Bronchoalveolar lavage reveals lymphocytic predominance (65%) with CD4:CD8 ratio of 0.8. Pulmonary function tests show a restrictive pattern with severely reduced DLCO (38% predicted). Which of the following is the most appropriate next step in management?", "options": ["Initiate high-dose intravenous methylprednisolone followed by oral prednisone 1 mg/kg/day", "Add mycophenolate mofetil to current immunosuppression", "Discontinue hydroxychloroquine and observe for 4 weeks", "Perform surgical lung biopsy to confirm usual interstitial pneumonia pattern", "Start rituximab therapy without additional testing"], "answer": "B", "answer_index": 1, "explanation": "The presentation is classic for lymphocytic interstitial pneumonia (LIP) associated with SLE, characterized by ground-glass opacities with reticulation, lymphocytic BAL, and low CD4:CD8 ratio. LIP in connective tissue disease typically requires more aggressive immunosuppression beyond steroids alone. Mycophenolate mofetil is the preferred steroid-sparing agent for SLE-associated interstitial lung disease with this pattern. High-dose steroids alone (A) are insufficient for progressive LIP. Hydroxychloroquine cessation (C) is unlikely to reverse established ILD. Surgical biopsy (D) is unnecessary with characteristic HRCT and BAL findings. Rituximab (E) is reserved for refractory cases after conventional immunosuppression fails.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with progressive dyspnea and dry cough, which are symptoms suggestive of an active lung process, potentially interstitial lung disease (ILD) or lupus pneumonitis, given her history of SLE.\n\nLet's analyze the findings:\n*   History of SLE: SLE can involve the lungs in multiple ways, including pneumonitis, pulmonary vasculitis, and ILD.\n*   Clinical presentation: Progressive dyspnea on exertion and dry cough over 3 weeks indicate an ongoing, worsening process rather than a chronic, stable condition.\n*   High-resolution CT (HRCT): Diffuse ground-glass opacities (GGOs) with superimposed fine reticulation and subpleural sparing. GGOs suggest active inflammation or edema within the alveoli and interstitium. Fine reticulation indicates interstitial thickening. Subpleural sparing is a pattern that can be seen in various ILDs, including hypersensitivity pneumonitis and organizing pneumonia, and may also occur in some patterns of SLE-related ILD.\n*   Bronchoalveolar lavage (BAL): Lymphocytic predominance (65%) with a CD4:CD8 ratio of 0.8. Lymphocytic alveolitis is a common finding in inflammatory lung diseases associated with autoimmune conditions like SLE. A CD4:CD8 ratio less than 1 can be observed in several interstitial lung diseases, but the lymphocytic predominance itself is a key indicator of inflammation.\n*   Pulmonary function tests (PFTs): Restrictive lung pattern with severely reduced DLCO (38%). A restrictive pattern indicates reduced lung volumes. A severely reduced DLCO points to significant impairment in gas exchange across the alveolar-capillary membrane, which can be caused by interstitial thickening, inflammation, or destruction of lung parenchyma.\n\nConsidering the differential diagnoses for lung involvement in SLE:\n1.  Lupus Pneumonitis: This is an acute inflammatory process of the lung parenchyma. It often presents with dyspnea, cough, and can cause GGOs, consolidation, or atelectasis on imaging. BAL typically shows lymphocytic alveolitis. It is often responsive to high-dose corticosteroids.\n2.  SLE-associated Interstitial Lung Disease (SLE-ILD): SLE can be associated with various patterns of ILD, including nonspecific interstitial pneumonia (NSIP)-like, organizing pneumonia (OP)-like, or even UIP-like patterns, though NSIP is more common. The described CT pattern with GGOs and reticulation could fit an inflammatory ILD.\n3.  Drug-Induced Lung Disease: Hydroxychloroquine could cause ILD, but this is usually slower in onset and may have different HRCT findings. The lymphocytic BAL and progressive, acute symptoms make a simpler drug toxicity less likely as the primary driver compared to active SLE inflammation.\n\nEvaluation of Options:\n*   A. Initiate high-dose intravenous methylprednisolone followed by oral prednisone 1 mg/kg/day: This is the standard of care for acute, severe inflammatory lung disease in SLE, such as lupus pneumonitis or an acute exacerbation of SLE-ILD. The patient's presentation (progressive symptoms, GGOs, lymphocytic alveolitis, PFT abnormalities) strongly suggests such a process. Prompt immunosuppression is crucial to prevent further lung damage and improve gas exchange.\n*   B. Add mycophenolate mofetil to current immunosuppression: Mycophenolate mofetil is a valid option for managing SLE manifestations and ISL, but it's generally not the first step in acute, severe, life-threatening lung inflammation. High-dose steroids are typically initiated first.\n*   C. Discontinue hydroxychloroquine and observe for 4 weeks: While hydroxychloroquine-induced ILD is a possibility, it's less likely given the BAL findings and the acute nature of the presentation. Discontinuing a proven beneficial medication like hydroxychloroquine without strong evidence for causality or alternative immediate treatment is not the most appropriate first step.\n*   D. Perform surgical lung biopsy to confirm usual interstitial pneumonia pattern: Surgical lung biopsy is an invasive procedure. The HRCT findings do not definitively show a UIP pattern, and the clinical context strongly suggests an inflammatory process related to SLE that is likely treatable with immunosuppression. Biopsy is usually reserved for diagnostic dilemmas or when empiric treatment fails.\n*   E. Start rituximab therapy without additional testing: Rituximab is a B-cell depleting agent used for severe or refractory SLE, but it is not typically the first-line treatment for acute lupus pneumonitis or ILD.\n\nThe most appropriate next step in managing a patient with active, progressive inflammatory lung disease associated with SLE, as suggested by the current findings, is to initiate aggressive immunosuppression with high-dose corticosteroids.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-002", "question": "A 62-year-old man with metastatic renal cell carcinoma on nivolumab and ipilimumab presents with acute-onset diplopia, ptosis, and dysphagia 6 weeks after initiation. Neurological exam reveals bilateral asymmetric ophthalmoparesis, fatigable ptosis, proximal muscle weakness, and normal pupillary responses. Repetitive nerve stimulation shows 25% decrement at 3Hz. Which of the following is the most specific diagnostic test to confirm the underlying pathophysiology?", "options": ["Anti-acetylcholine receptor antibody titer", "Anti-MuSK antibody testing", "Anti-LRP4 antibody assay", "CT chest with contrast for thymoma", "Serum anti-striational muscle antibody testing"], "answer": "E", "answer_index": 4, "explanation": "This presentation represents immune checkpoint inhibitor-induced myasthenia gravis, which is strongly associated with anti-striational muscle antibodies (particularly anti-titin) in paraneoplastic contexts. While anti-AChR antibodies (A) are positive in most generalized MG, anti-striational antibodies have higher specificity for thymoma-associated and paraneoplastic MG in cancer patients on immunotherapy. Anti-MuSK (B) and anti-LRP4 (C) antibodies are associated with different MG subtypes but not specifically with paraneoplastic forms. CT for thymoma (D) is indicated but not the most specific test for pathophysiology. The combination of immune checkpoint therapy with these neurological findings makes anti-striational antibodies the key diagnostic marker.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient presents with acute-onset neurological symptoms including diplopia, ptosis, and dysphagia, along with fatigable ptosis and proximal muscle weakness. Repetitive nerve stimulation shows a decrement, strongly suggesting a disorder of neuromuscular transmission, such as myasthenia gravis (MG). The patient is on nivolumab and ipilimumab, immunotherapies known to unmask or induce autoimmune conditions.\n\nThe question asks for the most specific diagnostic test to confirm the underlying pathophysiology. In the context of suspected MG, the underlying pathophysiology is an autoimmune attack on the neuromuscular junction. Let's evaluate the options:\n\nA. Anti-acetylcholine receptor (AChR) antibody titer: These antibodies are the most common cause of MG, found in about 85-90% of patients with generalized MG. They directly target the receptors essential for neuromuscular transmission, leading to impaired signal transduction. A positive test is highly specific for the autoimmune pathophysiology of MG.\n\nB. Anti-MuSK (muscle-specific kinase) antibody testing: These antibodies are found in about 5-10% of MG patients, often associated with more severe bulbar symptoms. While specific for MuSK-MG, it represents a less common pathway of autoimmunity compared to AChR antibodies.\n\nC. Anti-LRP4 (low-density lipoprotein receptor-related protein 4) antibody assay: These antibodies are found in a small subset (1-5%) of MG patients who are seronegative for AChR and MuSK antibodies. They are specific for this rarer subtype.\n\nD. CT chest with contrast for thymoma: Thymoma is a commonly associated condition with MG, particularly late-onset MG. However, a CT scan identifies a potential underlying cause or associated pathology of MG, not the direct autoimmune pathophysiology at the neuromuscular junction itself.\n\nE. Serum anti-striational muscle antibody testing: Striational antibodies (e.g., anti-titin antibodies) are found in about 30-50% of MG patients, especially those with thymoma and late-onset MG. While associated with MG, they are less directly indicative of the functional defect at the neuromuscular junction compared to antibodies targeting AChR or MuSK.\n\nThe question asks for the *most specific* diagnostic test to confirm *the* underlying pathophysiology. Given the classic presentation highly suggestive of MG, the most common and fundamental autoimmune attack occurs against the acetylcholine receptors at the neuromuscular junction. Therefore, testing for anti-AChR antibodies is the most specific test to confirm this predominant underlying pathophysiology. While anti-MuSK and anti-LRP4 antibodies are also specific tests for particular subtypes of MG, the anti-AChR antibody test covers the vast majority of cases and the most direct impairment of neuromuscular transmission.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-003", "question": "A 34-year-old pregnant woman at 32 weeks gestation presents with acute-onset severe headache, photophobia, and confusion. BP is 150/95 mmHg. MRI brain shows bilateral cortical and subcortical edema predominantly in posterior parietal and occipital lobes, with patchy cortical diffusion restriction. MR venography is normal. She has no proteinuria. Which of the following is the most likely underlying vascular pathophysiology?", "options": ["Cerebral venous sinus thrombosis", "Posterior reversible encephalopathy syndrome", "Reversible cerebral vasoconstriction syndrome", "Eclampsia without hypertension", "Posterior circulation ischemic stroke"], "answer": "C", "answer_index": 2, "explanation": "This represents reversible cerebral vasoconstriction syndrome (RCVS) in pregnancy, characterized by thunderclap headache, normal venography, and posterior-predominant edema with diffusion restriction. The key distinction from PRES (B) is the presence of cortical diffusion restriction and more severe headache. RCVS involves segmental cerebral arterial vasoconstriction rather than hypertensive breakthrough autoregulation. Cerebral venous thrombosis (A) would show venous occlusion. Eclampsia (D) typically requires significant hypertension and proteinuria. Posterior circulation stroke (E) would show more defined arterial territory infarction rather than patchy cortical involvement.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with acute-onset severe headache, photophobia, and confusion, along with elevated blood pressure (150/95 mmHg) at 32 weeks gestation. The MRI brain reveals bilateral cortical and subcortical edema predominantly in the posterior parietal and occipital lobes, with patchy cortical diffusion restriction. MR venography is normal, and there is no proteinuria.\n\nLet's analyze each option:\n\nA. Cerebral venous sinus thrombosis (CVST): CVST can cause headache and neurological deficits, but the MR venography is stated as normal, which rules out significant venous sinus thrombosis as the primary cause.\n\nB. Posterior reversible encephalopathy syndrome (PRES): PRES is characterized by vasogenic edema, typically affecting the posterior cerebral white matter, frontal lobes, and cerebellum. Common symptoms include headache, visual disturbances (like photophobia), altered mental status, and seizures. Hypertension is a frequent precipitating factor, as seen in this patient (150/95 mmHg). The MRI findings—bilateral cortical and subcortical edema predominantly in posterior parietal and occipital lobes—are classic for PRES. Patchy diffusion restriction can also be seen in PRES. PRES is common in pregnancy, especially in the third trimester, and can occur in the context of pre-eclampsia or simply due to elevated blood pressure. The absence of proteinuria does not exclude PRES, as it can occur with hypertension alone or precede the development of overt pre-eclampsia.\n\nC. Reversible cerebral vasoconstriction syndrome (RCVS): RCVS is characterized by recurrent thunderclap headaches and segmental narrowing of cerebral arteries. While it can lead to stroke or hemorrhage, the diffuse posterior edema pattern described is more typical of PRES. Imaging in RCVS typically shows multifocal vasoconstriction.\n\nD. Eclampsia without hypertension: Eclampsia is defined as seizures in a patient with pre-eclampsia. Hypertension is typically a diagnostic criterion for pre-eclampsia, so \"eclampsia without hypertension\" is a contradictory term. While eclampsia is a severe manifestation of hypertensive disorders in pregnancy and can involve PRES-like changes, the question asks for the *underlying vascular pathophysiology*, and the specific MRI findings are most directly described as PRES. Furthermore, the patient *does* have hypertension.\n\nE. Posterior circulation ischemic stroke: While the symptoms and some imaging findings (diffusion restriction) might suggest ischemia, the extensive bilateral cortical and subcortical edema predominantly in the posterior regions is a more characteristic pattern for PRES rather than a typical ischemic stroke, which tends to follow specific arterial territories.\n\nConsidering the constellation of symptoms, elevated blood pressure, gestational age, and classic MRI findings of posterior bilateral edema, Posterior Reversible Encephalopathy Syndrome (PRES) is the most likely diagnosis. PRES represents a microvascular disorder leading to breakdown of the blood-brain barrier and vasogenic edema.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-004", "question": "A 57-year-old man with alcoholic cirrhosis (Child-Pugh B) presents with fever, abdominal pain, and altered mental status. Paracentesis reveals ascitic fluid with 450 neutrophils/mm³. Blood and ascitic fluid cultures grow extended-spectrum beta-lactamase (ESBL) producing Escherichia coli. He receives meropenem for 72 hours but remains febrile with worsening encephalopathy. Repeat paracentesis shows 520 neutrophils/mm³ with negative cultures. Which of the following is the most appropriate next step?", "options": ["Add intravenous vancomycin for possible MRSA coverage", "Switch to piperacillin-tazobactam given ESBL resistance patterns", "Perform urgent transjugular intrahepatic portosystemic shunt placement", "Administer intravenous albumin 1.5 g/kg on day 1 and 1.0 g/kg on day 3", "Add intravenous metronidazole for anaerobic coverage"], "answer": "C", "answer_index": 2, "explanation": "This scenario describes recurrent or persistent spontaneous bacterial peritonitis (SBP) with treatment failure, which in the context of cirrhosis carries high mortality. TIPS placement reduces portal pressure and may improve outcomes in refractory SBP by decreasing bacterial translocation. Albumin (D) is indicated for SBP but already should have been given initially. Antibiotic changes (A, B, E) are inappropriate with negative repeat cultures and clinical deterioration despite appropriate initial therapy. In refractory SBP with ongoing inflammation despite adequate antibiotics, TIPS can be life-saving by addressing the underlying pathophysiology of portal hypertension.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient has spontaneous bacterial peritonitis (SBP) caused by ESBL-producing *E. coli*. He initially received meropenem, a carbapenem, which is an appropriate choice for ESBL-producing organisms. However, he has not improved after 72 hours of therapy and is experiencing worsening encephalopathy. This indicates treatment failure or development of complications.\n\nLet's evaluate the options:\n\nA. Add intravenous vancomycin for possible MRSA coverage: The identified pathogen is *E. coli*, a Gram-negative bacterium. Vancomycin covers Gram-positive bacteria like MRSA. There is no indication of MRSA infection.\n\nB. Switch to piperacillin-tazobactam given ESBL resistance patterns: ESBL-producing organisms are often resistant to penicillins and cephalosporins, but carbapenems like meropenem are typically effective. If meropenem is failing, it could indicate resistance to carbapenems themselves (e.g., production of carbapenemases) or other factors. Piperacillin-tazobactam's efficacy against ESBL-producing strains is variable and often less potent than carbapenems. Switching to piperacillin-tazobactam might not be effective and could be suboptimal if the *E. coli* has acquired broader resistance mechanisms.\n\nC. Perform urgent transjugular intrahepatic portosystemic shunt placement: TIPS is indicated for complications of portal hypertension such as refractory ascites or variceal bleeding. It is not an acute treatment for SBP or worsening encephalopathy in the context of infection.\n\nD. Administer intravenous albumin 1.5 g/kg on day 1 and 1.0 g/kg on day 3: In patients with SBP, particularly those with Child-Pugh B or C cirrhosis, administration of intravenous albumin along with antibiotics has been shown to reduce the incidence of renal impairment and mortality. Worsening encephalopathy in a cirrhotic patient with SBP can be multifactorial, but renal dysfunction (hepato-renal syndrome) is a significant contributor. Albumin administration helps maintain oncotic pressure, improves circulatory volume, and supports renal function. Given the patient's Child-Pugh B status and his worsening clinical condition, including encephalopathy, optimizing albumin therapy is a critical and evidence-based next step to improve outcomes and manage complications.\n\nE. Add intravenous metronidazole for anaerobic coverage: The identified pathogen is *E. coli*, which is an aerobic Gram-negative bacterium. Anaerobes are not typical pathogens for SBP. Therefore, adding metronidazole, which covers anaerobes, is inappropriate.\n\nConsidering the patient's decompensated liver disease (Child-Pugh B), the failure to improve SBP, and the worsening encephalopathy, aggressive supportive care is paramount. Albumin administration is a proven method to improve outcomes in SBP patients with moderate to severe liver disease.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-005", "question": "A 41-year-old woman with antiphospholipid syndrome (triple positive) on warfarin (INR 2.8) presents with acute right hemiparesis and aphasia. CT angiogram shows complete occlusion of the left middle cerebral artery M1 segment. She is 4 hours from symptom onset. Which of the following is the most appropriate acute intervention?", "options": ["Administer intravenous tissue plasminogen activator", "Proceed with mechanical thrombectomy without thrombolysis", "Give intravenous heparin bolus followed by infusion", "Administer intra-arterial thrombolysis via catheter", "Continue warfarin and add aspirin 325 mg"], "answer": "B", "answer_index": 1, "explanation": "In antiphospholipid syndrome with acute large vessel occlusion, mechanical thrombectomy is indicated regardless of anticoagulation status. tPA (A) is contraindicated with therapeutic INR >1.7. Heparin (C) adds bleeding risk without proven benefit in acute stroke with therapeutic anticoagulation. Intra-arterial thrombolysis (D) carries similar bleeding risks as IV tPA. Continuing warfarin with aspirin (E) does not address acute occlusion. Mechanical thrombectomy has shown benefit up to 24 hours in selected patients and is not contraindicated by therapeutic anticoagulation if the procedure can be performed safely.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms of acute ischemic stroke (right hemiparesis, aphasia) and imaging showing a large vessel occlusion (LVO) of the left Middle Cerebral Artery (MCA) M1 segment. The onset of symptoms was 4 hours prior, placing her within the treatment window for reperfusion therapies.\n\nLet's evaluate the options:\n\nA.  Administer intravenous tissue plasminogen activator (IV tPA): IV tPA is indicated for acute ischemic stroke within 4.5 hours of symptom onset. However, a significant contraindication for IV tPA administration is an elevated international normalized ratio (INR). Standard guidelines typically recommend an INR less than 1.7 for administering IV tPA. This patient's INR is 2.8, which is within the therapeutic range for warfarin but is generally considered too high for safe administration of IV tPA due to an increased risk of intracranial hemorrhage. Therefore, IV tPA is likely contraindicated in this patient.\n\nB.  Proceed with mechanical thrombectomy without thrombolysis: Mechanical thrombectomy is a highly effective treatment for acute ischemic stroke with LVOs, such as an MCA M1 occlusion, and is recommended for patients who can be treated within 6 hours of symptom onset (and potentially up to 24 hours in selected cases). Since the patient has an LVO and is within the time window, mechanical thrombectomy is a strong consideration. Given the likely contraindication to IV tPA due to her INR of 2.8, proceeding directly with mechanical thrombectomy without thrombolysis is the most appropriate reperfusion strategy. The fact that she has antiphospholipid syndrome (APS) and is on warfarin implies a hypercoagulable state, but this does not preclude mechanical reperfusion therapy.\n\nC.  Give intravenous heparin bolus followed by infusion: Acute anticoagulation with heparin is generally not the primary treatment for resolving an arterial occlusion in acute ischemic stroke. It does not directly restore blood flow and can increase the risk of bleeding, especially if thrombolysis or thrombectomy is considered.\n\nD.  Administer intra-arterial thrombolysis via catheter: Intra-arterial thrombolysis was a treatment option before the advent of mechanical thrombectomy. Mechanical thrombectomy has largely replaced intra-arterial thrombolysis for LVO strokes due to superior efficacy and potentially lower procedural risks in many cases.\n\nE.  Continue warfarin and add aspirin 325 mg: This approach describes secondary prevention rather than acute reperfusion. In the acute phase of LVO stroke, the priority is to restore blood flow. Adding aspirin to therapeutic warfarin acutely would significantly increase bleeding risk without addressing the immediate occlusion. Management of antithrombotic therapy for APS patients post-stroke is complex but begins after the acute reperfusion phase.\n\nBased on the patient's presentation of an LVO stroke within the time window and the contraindication for IV tPA due to her INR, mechanical thrombectomy without thrombolysis is the most appropriate acute intervention.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-006", "question": "A 29-year-old woman presents with 6 months of progressive dyspnea and palpitations. Echocardiogram shows severe pulmonary hypertension (RVSP 85 mmHg) with right ventricular dilation but normal left heart function. Right heart catheterization confirms pre-capillary pulmonary hypertension (mPAP 48 mmHg, PAWP 10 mmHg). High-resolution CT shows mosaic attenuation and enlarged central pulmonary arteries. Ventilation-perfusion scan reveals multiple segmental perfusion defects. Which of the following is the definitive diagnostic test?", "options": ["Pulmonary angiogram", "CT pulmonary angiogram", "Genetic testing for BMPR2 mutation", "Lung biopsy", "Exercise right heart catheterization"], "answer": "A", "answer_index": 0, "explanation": "This presentation is classic for chronic thromboembolic pulmonary hypertension (CTEPH). While V/Q scan is the screening test, pulmonary angiography remains the gold standard for defining surgical accessibility and planning pulmonary endarterectomy. CT pulmonary angiography (B) provides anatomical detail but has lower sensitivity for chronic thromboembolic material. Genetic testing (C) is for heritable pulmonary arterial hypertension, not CTEPH. Lung biopsy (D) is contraindicated in severe pulmonary hypertension. Exercise catheterization (E) may confirm exercise-induced PH but doesn't diagnose CTEPH. Pulmonary angiography is essential for determining operability in CTEPH.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Rationale Breakdown:\nThe patient presents with symptoms and hemodynamic findings of severe pre-capillary pulmonary hypertension (PH). The key diagnostic clue is the ventilation-perfusion (V/Q) scan revealing multiple segmental perfusion defects. This finding is highly suggestive of chronic thromboembolic pulmonary hypertension (CTEPH), where organized blood clots obstruct pulmonary arteries, leading to diminished blood flow to lung segments. The high-resolution CT findings of mosaic attenuation (which can indeed be seen in CTEPH due to chronic perfusion deficits) and enlarged central pulmonary arteries are also consistent with PH, and the mosaic pattern can further indirectly support vascular obstruction.\n\nLet's evaluate the options in the context of suspected CTEPH:\n\nA. Pulmonary angiogram: While historically used, CT pulmonary angiogram (CTPA) has largely replaced conventional pulmonary angiography for the diagnosis of CTEPH due to its lower invasiveness, better spatial resolution in many cases, and ability to assess lung parenchyma simultaneously. It can demonstrate filling defects, webs, and obstructions.\n\nB. CT pulmonary angiogram (CTPA): This is the imaging modality of choice for evaluating suspected CTEPH. It provides detailed visualization of the pulmonary arteries, allowing for the detection of organized thrombi, stenosis, webs, and other vascular abnormalities characteristic of CTEPH. The findings on CTPA are crucial for confirming the diagnosis and assessing the extent and location of disease, which is essential for determining eligibility for surgical treatment (pulmonary endarterectomy). Given the strong suspicion for CTEPH based on the V/Q scan, CTPA is the definitive imaging test.\n\nC. Genetic testing for BMPR2 mutation: BMPR2 mutations are associated with heritable pulmonary arterial hypertension (HPAH), which is a form of pulmonary arterial hypertension (PAH). PAH is characterized by remodeling of small pulmonary arteries, not necessarily large vessel obstruction seen on V/Q scans with perfusion defects. While other forms of PH exist, the V/Q scan is very specific for CTEPH. Thus, genetic testing for BMPR2 mutation is not the definitive test for the suspected diagnosis here.\n\nD. Lung biopsy: Lung biopsy is typically not indicated for the diagnosis of CTEPH. It is more commonly used to diagnose interstitial lung diseases or vasculitis, which are different etiologies of PH. The findings on V/Q and CTPA are far more specific for CTEPH.\n\nE. Exercise right heart catheterization: The patient already has severe resting PH confirmed by right heart catheterization. Exercise RHC is used to assess hemodynamic response to exertion, not to establish the initial diagnosis of severe resting PH or its specific cause like CTEPH.\n\nConclusion: The V/Q scan showing segmental perfusion defects strongly points towards CTEPH. CTPA is the standard and most definitive diagnostic test for evaluating CTEPH.\n\nThe final answer is $\\boxed{B}$"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-007", "question": "A 63-year-old man with diabetes and peripheral arterial disease presents with 2 hours of acute, painless monocular vision loss in the right eye. Visual acuity is hand motion only. Funduscopy reveals a pale retina with cherry-red spot and boxcarring of retinal vessels. Carotid duplex shows 90% stenosis of the right internal carotid artery. Which of the following is the most urgent intervention?", "options": ["Intravenous tissue plasminogen activator", "Anterior chamber paracentesis", "Immediate carotid endarterectomy", "Hyperbaric oxygen therapy", "Intra-arterial thrombolysis via ophthalmic artery catheterization"], "answer": "E", "answer_index": 4, "explanation": "This describes central retinal artery occlusion (CRAO) with cherry-red spot and boxcarring, indicating acute ischemia. Intra-arterial thrombolysis via selective ophthalmic artery catheterization within 6-12 hours may restore vision in CRAO, though evidence is limited. IV tPA (A) is not standard for CRAO. Anterior chamber paracentesis (B) is historical but ineffective. Carotid endarterectomy (C) addresses the source but not the acute occlusion. Hyperbaric oxygen (D) has limited evidence. Given the time window and severity, selective intra-arterial thrombolysis offers the best chance for visual recovery in this acute setting.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient presents with classic signs of central retinal artery occlusion (CRAO): acute, painless monocular vision loss, pale retina with a cherry-red spot, and boxcarring of retinal vessels. The cherry-red spot indicates that the inner retinal layers are ischemic but still have some perfusion, suggesting a potential window for intervention. The identified 90% stenosis of the ipsilateral internal carotid artery is a highly significant risk factor and is the most likely cause of the CRAO, either through embolization of plaque or thrombus from the stenosis site.\n\nThe question asks for the *most urgent* intervention. Let's analyze the options:\n\nA. Intravenous tissue plasminogen activator (tPA): This is a thrombolytic agent used for acute ischemic stroke. While it has been considered for CRAO, its efficacy and safety are less established compared to cerebral stroke. It would target the clot in the retinal artery but not the source of the embolus.\n\nB. Anterior chamber paracentesis: This procedure lowers intraocular pressure and is not indicated for CRAO.\n\nC. Immediate carotid endarterectomy: This surgical procedure removes atherosclerotic plaque from the carotid artery, addressing the source of the embolization causing the CRAO and significantly reducing the risk of future embolic events, including cerebral stroke. For patients with symptomatic severe carotid stenosis (which CRAO can be considered), urgent intervention is often recommended. A 90% stenosis represents a very high risk for further embolization. Addressing this critical vascular lesion is paramount for preventing both recurrent ocular events and potentially devastating cerebral strokes.\n\nD. Hyperbaric oxygen therapy: This can be an adjunctive therapy for CRAO, but it is not the primary or most urgent intervention, especially in the presence of a correctable severe arterial stenosis.\n\nE. Intra-arterial thrombolysis via ophthalmic artery catheterization: This is a more invasive form of thrombolysis targeting the clot directly. Similar to IV tPA, it addresses the clot but not the source of emboli and is associated with risks.\n\nConsidering the presence of severe (90%) carotid stenosis as the likely cause of the CRAO, addressing this critical underlying pathology is the most urgent and definitive intervention to prevent recurrent events and further neurological damage. While thrombolysis might offer a chance of restoring vision if performed very early, the persistent 90% stenosis poses an immediate and ongoing threat. In cases of stroke with severe ipsilateral carotid stenosis, urgent carotid endarterectomy is generally indicated. Therefore, immediate carotid endarterectomy is the most urgent intervention to address the root cause and protect the patient from further embolic events.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-008", "question": "A 38-year-old woman with history of mitral valve prolapse presents with 3 weeks of daily fevers, night sweats, and new-onset diastolic murmur. Blood cultures are negative after 72 hours. Transthoracic echocardiogram shows a 12mm mobile vegetation on the anterior mitral leaflet with severe mitral regurgitation. Which of the following organisms is most likely responsible?", "options": ["Streptococcus gallolyticus", "Coxiella burnetii", "Bartonella henselae", "Tropheryma whipplei", "Abiotrophia defectiva"], "answer": "C", "answer_index": 2, "explanation": "This presentation suggests culture-negative endocarditis in a patient with pre-existing mitral valve disease. Bartonella henselae is the most common cause of culture-negative endocarditis in patients with valve abnormalities, particularly associated with negative blood cultures, subacute presentation, and large vegetations. Coxiella burnetii (B) typically causes Q fever endocarditis with exposure history. Streptococcus gallolyticus (A) is culture-positive and associated with colorectal pathology. Tropheryma whipplei (D) causes Whipple's disease with systemic symptoms. Abiotrophia (E) is nutritionally variant but usually culture-positive. Bartonella requires serology or PCR for diagnosis and responds to specific antibiotic regimens.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with symptoms classic for subacute bacterial endocarditis: prolonged fever, night sweats, and a new heart murmur. The history of mitral valve prolapse is a significant risk factor for infective endocarditis. The echocardiogram confirms the presence of a vegetation on the mitral valve with severe regurgitation, establishing the diagnosis of endocarditis. The key finding that narrows down the differential is the negative blood cultures after 72 hours, indicating an organism that is difficult to culture using standard methods.\n\nLet's evaluate the options:\nA. Streptococcus gallolyticus: While a cause of endocarditis, it is typically cultured positive on standard blood cultures and is strongly associated with colonic pathology.\nB. Coxiella burnetii: This organism causes Q fever, and Q fever endocarditis is a well-known and serious complication. It characteristically presents with negative routine blood cultures for bacteria, prolonged fever, and can cause significant valvular damage, particularly on the aortic and mitral valves. The patient's presentation aligns very well with Q fever endocarditis.\nC. Bartonella henselae: Bartonella species are known causes of culture-negative endocarditis, particularly in immunocompromised individuals or those with prosthetic valves. While possible, it's less classically associated with this specific presentation than Coxiella burnetii.\nD. Tropheryma whipplei: This organism causes Whipple's disease, and endocarditis can be an unusual manifestation, leading to culture-negative endocarditis. However, isolated endocarditis without other systemic symptoms of Whipple's disease is less common, and Q fever endocarditis is a more frequent cause of culture-negative endocarditis in this context.\nE. Abiotrophia defectiva: These are nutritionally variant streptococci that require special media for growth and can lead to culture-negative endocarditis. While a possibility, Coxiella burnetii is a more prominent cause of severe culture-negative endocarditis with significant valvular damage in patients with pre-existing valvular disease.\n\nConsidering the combination of native valve disease, subacute symptoms, significant vegetation, severe valvular regurgitation, and negative routine blood cultures, Coxiella burnetii is the most likely culprit.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-009", "question": "A 52-year-old woman with rheumatoid arthritis on methotrexate presents with progressive dyspnea and dry cough. High-resolution CT shows extensive ground-glass opacities with centrilobular nodules and tree-in-bud pattern predominantly in upper lobes. Bronchoscopy with transbronchial biopsy reveals non-necrotizing granulomas with multinucleated giant cells. Which of the following is the most likely diagnosis?", "options": ["Methotrexate pneumonitis", "Rheumatoid arthritis-associated interstitial lung disease", "Mycobacterium avium complex infection", "Sarcoidosis", "Hypersensitivity pneumonitis"], "answer": "C", "answer_index": 2, "explanation": "The combination of upper lobe predominance, tree-in-bud pattern, and non-necrotizing granulomas in an immunocompromised patient on methotrexate is classic for nontuberculous mycobacterial infection, particularly MAC. Methotrexate pneumonitis (A) typically shows diffuse alveolar damage pattern. RA-ILD (B) usually shows UIP or NSIP patterns. Sarcoidosis (D) shows perilymphatic nodules and hilar adenopathy. Hypersensitivity pneumonitis (E) shows centrilobular nodules but usually without tree-in-bud or upper lobe predominance. Immunosuppressed patients on methotrexate are at increased risk for NTM infections, which can mimic granulomatous diseases.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with progressive dyspnea and dry cough, symptoms suggestive of interstitial lung disease (ILD). Her medical history includes rheumatoid arthritis (RA) and treatment with methotrexate (MTX), both of which increase the risk of lung complications.\n\nLet's analyze the findings:\n1.  High-Resolution CT (HRCT) findings: Extensive ground-glass opacities (GGO), centrilobular nodules, tree-in-bud pattern, predominantly in upper lobes.\n    *   GGO and nodules are non-specific findings seen in various ILDs, infections, and inflammatory conditions.\n    *   The \"tree-in-bud\" pattern is highly suggestive of infectious bronchiolitis or other conditions causing small airway obstruction or impaction, such as *Mycobacterium* species, *Nocardia*, or aspiration.\n    *   Upper lobe predominance can be seen in conditions like tuberculosis, sarcoidosis, silicosis, and rheumatoid arthritis-associated ILD with fibrosis.\n\n2.  Bronchoscopy with transbronchial biopsy findings: Non-necrotizing granulomas with multinucleated giant cells.\n    *   The presence of non-necrotizing granulomas is a hallmark histological feature of sarcoidosis.\n    *   While granulomas can also be seen in infections (e.g., tuberculosis, fungal infections), they are often necrotizing. However, non-necrotizing granulomas can occur in atypical mycobacterial infections like MAC.\n\nNow let's evaluate the options:\nA.  Methotrexate pneumonitis: MTX can cause various lung reactions, including pneumonitis, organizing pneumonia, or fibrosis. However, typical MTX pneumonitis is not characterized by granuloma formation.\nB.  Rheumatoid arthritis-associated interstitial lung disease: RA-ILD can present with various HRCT patterns, often with basal or subpleural predominance of fibrosis. Granulomas are not a typical histological feature of RA-ILD itself.\nC.  Mycobacterium avium complex (MAC) infection: MAC infection can present with dyspnea and cough. HRCT findings can include nodules, GGO, and importantly, the tree-in-bud pattern with upper lobe predominance, which is highly characteristic. MAC infection can elicit a granulomatous response, and these granulomas are not always necrotizing. Given the patient's MTX use, opportunistic infections like MAC are a concern.\nD.  Sarcoidosis: Sarcoidosis is defined by non-necrotizing granulomas and typically affects the lungs. While classic CT findings include bilateral hilar lymphadenopathy and perilymphatic nodules, sarcoidosis can present with other patterns including GGO, nodules, and upper lobe predominance. Airway involvement can occur, potentially leading to tree-in-bud appearance, although this is less typical than the perilymphatic distribution. The biopsy findings strongly support sarcoidosis.\nE.  Hypersensitivity pneumonitis (HP): HP causes inflammation of the lung parenchyma due to an immune response to inhaled antigens. Subacute and chronic HP can cause GGO, nodules, and fibrosis, often with lower or mid-lung predominance, though upper lobe involvement is possible. Granulomas can be seen in HP, but they are often poorly formed, and non-necrotizing granulomas are most strongly associated with sarcoidosis.\n\nDecision Making:\nThis question presents a conflict between a highly suggestive CT finding (tree-in-bud pattern for infection like MAC) and a highly suggestive (potentially pathognomonic) histological finding (non-necrotizing granulomas for sarcoidosis).\n\n*   The tree-in-bud pattern is a strong indicator of infectious bronchiolitis. MAC is a prime pathogen. The patient's MTX use is a risk factor for MAC.\n*   Non-necrotizing granulomas are the defining feature of sarcoidosis.\n\nHowever, in distinguishing between granulomatous infections and sarcoidosis, the morphology of granulomas is crucial. The term \"non-necrotizing\" is specifically used to differentiate from typical caseating granulomas seen in tuberculosis (though MAC can also form caseating granulomas). Therefore, the biopsy finding of non-necrotizing granulomas strongly points towards sarcoidosis. While the CT findings are not the absolute classic presentation of sarcoidosis (e.g., absence of mentioned hilar lymphadenopathy), sarcoidosis can have varied appearances, including airway involvement that might manifest as tree-in-bud patterns on CT. Conversely, while MAC can present with granulomas, the specific description of \"non-necrotizing granulomas\" is most definitively associated with sarcoidosis. Given the options and the specificity of histological findings, sarcoidosis is the most likely diagnosis.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed124", "question_id": "20251205T082731900Z_deepseek-v3.2_seed124-010", "question": "A 44-year-old woman presents with 8 months of progressive proximal muscle weakness, heliotrope rash, and Gottron's papules. Muscle biopsy shows perfascicular atrophy and MAC deposition on capillaries. She tests positive for anti-MDA5 antibodies. Which of the following complications carries the highest immediate mortality risk?", "options": ["Aspiration pneumonia", "Cardiac conduction abnormalities", "Rapidly progressive interstitial lung disease", "Malignancy-associated deterioration", "Calcinosis universalis"], "answer": "C", "answer_index": 2, "explanation": "Anti-MDA5 antibody-positive dermatomyositis is strongly associated with rapidly progressive interstitial lung disease (RP-ILD), which has mortality exceeding 50% within 6 months despite treatment. This subtype shows characteristic skin findings but often minimal muscle involvement, with MAC deposition on capillaries. While aspiration (A) and cardiac issues (B) occur in myositis, RP-ILD is the most lethal complication in anti-MDA5 patients. Malignancy risk (D) is lower with anti-MDA5 than with anti-TIF1γ. Calcinosis (E) is chronic but not immediately life-threatening. Early recognition and aggressive immunosuppression for RP-ILD are critical in anti-MDA5 dermatomyositis.", "generator_model": "deepseek-v3.2", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient's presentation of proximal muscle weakness, heliotrope rash, and Gottron's papules, along with characteristic muscle biopsy findings and positive anti-MDA5 antibodies, is highly indicative of dermatomyositis with a specific immunophenotype. Anti-MDA5 antibody-positive dermatomyositis is strongly associated with a distinct clinical pattern, often including amyopathic disease (minimal muscle weakness) or subacute onset, prominent cutaneous features (like heliotrope rash, Gottron's sign, ulcerative lesions), and a significant risk of interstitial lung disease (ILD).\n\nLet's analyze the options in the context of anti-MDA5 positive dermatomyositis:\n\nA. Aspiration pneumonia: While muscle weakness and dysphagia can predispose to aspiration pneumonia, and ILD can worsen respiratory compromise, aspiration pneumonia is a secondary complication that may arise, but it's not the *primary immediate* life-threatening complication directly driven by the underlying disease process itself compared to others.\n\nB. Cardiac conduction abnormalities: Cardiac involvement can occur in inflammatory myopathies, but it is typically less frequent and less severe in dermatomyositis compared to polymyositis or inclusion body myositis. Anti-MDA5 dermatomyositis is not specifically characterized by a high risk of immediate cardiac conduction abnormalities as its dominant threat.\n\nC. Rapidly progressive interstitial lung disease (RP-ILD): This is a well-established and notorious complication of anti-MDA5 antibody-positive dermatomyositis. Many patients with this antibody subtype develop severe, rapidly progressive ILD that can lead to acute respiratory failure and death, often very quickly. This ILD can appear even in the absence of significant muscle weakness (amyopathic dermatomyositis). Given the promptness and severity, RP-ILD represents the highest immediate mortality risk.\n\nD. Malignancy-associated deterioration: Dermatomyositis, in general, is associated with an increased risk of underlying malignancy. However, the specific association with anti-MDA5 antibodies points more strongly towards RP-ILD than an increased risk of malignancy as the primary immediate threat. While malignancy can cause deterioration, RP-ILD is often the more acute and immediate killer in this specific subtype.\n\nE. Calcinosis universalis: Calcinosis is a later complication of dermatomyositis and is characterized by calcium deposits in the skin, subcutaneous tissues, and muscles. While it can cause significant morbidity and disability, it is typically not associated with immediate mortality.\n\nConsidering the high propensity for rapid and severe lung involvement characteristic of anti-MDA5 positive dermatomyositis, rapidly progressive interstitial lung disease (RP-ILD) poses the most significant and immediate threat to life.\n\nThe answer is (C)"}]